Company profile for Zura Bio

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Zura Bio is a clinical-stage biotechnology company advancing ZB-168 in alopecia areata and other inflammatory diseases. ZB-168 is an anti IL7Rα inhibitor that has the potential to impact diseases driven by IL7 and TSLP biological pathways. Zura Bio aims to develop a portfolio of therapeutic indications for ZB-168, and is focused on demonstrating its efficacy, safety, dosing convenience and mechanism of action, initially in al...
Zura Bio is a clinical-stage biotechnology company advancing ZB-168 in alopecia areata and other inflammatory diseases. ZB-168 is an anti IL7Rα inhibitor that has the potential to impact diseases driven by IL7 and TSLP biological pathways. Zura Bio aims to develop a portfolio of therapeutic indications for ZB-168, and is focused on demonstrating its efficacy, safety, dosing convenience and mechanism of action, initially in alopecia areata. This will build on Phase 1b data in Type 1 Diabetes demonstrating a favourable safety profile and strong biological rationale. Zura Bio is headquartered in London, UK with team members in the UK and USA.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
United Kingdom
Address
Address
3rd Floor, 1 Ashley Road, Altrincham, Cheshire WA14 2DT, GB
Telephone
Telephone
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Natural Product Expo West

Natural Product Expo West

Not Confirmed

envelop Contact Supplier

Natural Product Expo West

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.pharmiweb.com/press-release/2026-03-02/zura-bio-to-participate-in-upcoming-investor-conferences

PHARMIWEB
02 Mar 2026

https://www.pharmiweb.com/press-release/2026-02-27/zura-bio-announces-closing-of-its-144-million-public-offering-and-full-exercise-of-the-underwriters

PHARMIWEB
27 Feb 2026

https://www.pharmiweb.com/press-release/2026-02-25/zura-bio-announces-pricing-of-125-million-public-offering-of-class-a-ordinary-shares-and-pre-funded

PHARMIWEB
25 Feb 2026

https://www.businesswire.com/news/home/20260224878732/en/Zura-Bio-Announces-Proposed-Public-Offering-of-Class-A-Ordinary-Shares-and-Pre-Funded-Warrants

BUSINESSWIRE
24 Feb 2026

https://www.pharmiweb.com/press-release/2026-02-23/zura-bio-welcomes-accomplished-drug-development-leaders-mark-eisner-md-mph-and-ajay-nirula

PHARMIWEB
23 Feb 2026

https://www.pharmiweb.com/press-release/2026-02-04/zura-bio-to-participate-in-the-guggenheim-emerging-outlook-biotech-summit

PHARMIWEB
04 Feb 2026

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty